Cerutti I, Chany C
Int J Immunopharmacol. 1985;7(5):783-7. doi: 10.1016/0192-0561(85)90166-3.
We have proposed an antitumor therapeutic model in mice grafted with Crocker 180TG cells. The treatment strategy involves a coordinated immune stimulation which should always precede treatment of target cells. Potent stimulators mobilizing the majority of immune competent cells can be injected only once since repetition results in adverse effects on the response. Thus, to circumvent this difficulty, we propose the amplification, after a single shot of Corynebacterium parvum extract, of the immune response by cimetidine. Indeed, it has been reported that cimetidine inhibits suppressor T cell functions. The second phase acting on the target employs interferon and arginine butyrate since they reconvert a number of transformed target cells to normal phenotype. Important antitumor effects can be obtained in the present model even if the treatment is initiated relatively late after tumor graft. All the drugs employed are harmless on normal cells and are used at relatively low concentrations.
我们已经在移植了克罗克180TG细胞的小鼠中提出了一种抗肿瘤治疗模型。治疗策略包括协同免疫刺激,这种刺激应始终先于对靶细胞的治疗。由于重复注射会对反应产生不利影响,因此动员大多数免疫活性细胞的强效刺激剂只能注射一次。因此,为了克服这一困难,我们建议在单次注射短小棒状杆菌提取物后,用西咪替丁增强免疫反应。事实上,据报道西咪替丁可抑制抑制性T细胞功能。作用于靶标的第二阶段采用干扰素和丁酰精氨酸,因为它们可使许多转化的靶细胞恢复正常表型。即使在肿瘤移植后相对较晚开始治疗,在当前模型中也可获得重要的抗肿瘤效果。所有使用的药物对正常细胞无害,且使用浓度相对较低。